Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inetetamab
- Development stage
- Phase 4
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Inetetamab is a humanized monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2/ErbB2). It is an Fc-engineered analog of trastuzumab, differing by two amino acids in the Fc domain while retaining an identical F(ab’)2 region. Inetetamab binds to domain IV of HER2 on tumor cells, blocking HER2-mediated signaling and inhibiting cancer cell proliferation. Its optimized Fc region enhances antibody-dependent cell-mediated cytotoxicity (ADCC) compared to trastuzumab. Inetetamab has demonstrated efficacy in HER2-positive advanced breast cancer and shows synergistic antitumor effects when combined with chemotherapeutic agents such as cisplatin or tyrosine kinase inhibitors. Developed and manufactured in China, it is primarily used for treating HER2-positive advanced or metastatic breast cancer.
- Brand names
- Cipterbin
- Other names
- trastuzumab biosimilarAprogen HER2 biosimilarAprogen trastuzumab biosimilar
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on inetetamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inetetamab.